Expand MYGN Menu
MYGN MENU

MYGN Latest Press Releases

-- August 8, 2026 --

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law Business Wire 2:57 PM

-- August 7, 2026 --

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm Globe Newswire 2:54 PM

-- August 6, 2026 --

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN) Globe Newswire 10:09 AM

-- August 5, 2026 --

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud Globe Newswire 8:00 PM
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN) Business Wire 10:07 AM

-- August 4, 2026 --

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Globe Newswire 11:27 AM
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics PRNewswire 10:07 AM

-- August 3, 2026 --

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) PRNewswire 6:14 PM

-- July 30, 2026 --

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability Globe Newswire 4:05 PM

-- July 23, 2026 --

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 Globe Newswire 9:05 AM

-- July 21, 2026 --

Myriad Genetics Launches FirstGene Multiple Prenatal Screen Globe Newswire 9:05 AM

-- July 2, 2026 --

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer Globe Newswire 9:05 AM

-- June 23, 2026 --

Myriad Genetics Expands Availability of Precise MRD for Colorectal, Renal and Breast Cancers, Supported by New Publication Globe Newswire 9:05 AM

-- June 2, 2026 --

Myriad Genetics Names Raj Jampa as New Chief Technology Officer Globe Newswire 9:05 AM

-- May 27, 2026 --

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting Globe Newswire 9:05 AM

-- May 26, 2026 --

Myriad Genetics Launches Prolaris + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) Globe Newswire 4:05 PM

-- May 15, 2026 --

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life Globe Newswire 11:00 AM

-- May 7, 2026 --

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences Globe Newswire 4:05 PM

-- May 5, 2026 --

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business Globe Newswire 4:05 PM

-- April 30, 2026 --

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan Globe Newswire 9:05 AM

-- April 28, 2026 --

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 Globe Newswire 4:05 PM

-- April 16, 2026 --

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 Globe Newswire 9:15 AM

-- April 14, 2026 --

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan Globe Newswire 9:15 AM

-- April 9, 2026 --

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting Globe Newswire 9:15 AM

-- March 17, 2026 --

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes